Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib with Bevacizumab and FOLFOX in Metastatic Colorectal Cancer
NCT00116506Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in metastatic colorectal cancer (mCRC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-Free Survival at 1 year. Started Jan 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00116506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116506.